Alprostadil/lidocaine - Apricus Biosciences

Drug Profile

Alprostadil/lidocaine - Apricus Biosciences

Alternative Names: NM02216; NM100061

Latest Information Update: 31 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NexMed
  • Developer Apricus Biosciences
  • Class Acetanilides; Erectile dysfunction therapies; Monounsaturated fatty acids; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Premature ejaculation

Most Recent Events

  • 10 Sep 2010 NexMed is now called Apricus Biosciences
  • 24 Mar 2004 Data from a media release have been added to the adverse events and Mens Health therapeutic trials sections
  • 22 Mar 2004 Phase-II clinical trials in Premature ejaculation in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top